WHO’s Blind Spot on U.S. Nicotine Pouch Regulation

When the World Health Organization (WHO) released its latest report (“Exposing marketing tactics and strategies driving the growth of nicotine pouches”) it framed nicotine pouches almost exclusively as a marketing problem—an industry tactic designed to addict a new generation. What the report largely omits, however, is an inconvenient truth: nicotine pouches are already regulated in at least one major market through one of the most stringent public‑health review systems in the world—and they passed.

That market is the United States. 

In January 2025, the U.S. Food and Drug Administration (FDA) authorized the first nicotine pouch products for legal sale after years of scientific review under its Premarket Tobacco Product Application (PMTA) framework. The FDA concluded that these specific nicotine pouch products met the legal standard of being “appropriate for the protection of public health”—a population‑level test mandated by Congress that weighs risks and benefits for both users and non‑users, including youth.

This decision matters because the FDA has explicit regulatory authority over nicotine pouches. They’re defined as tobacco products under U.S. law and cannot be marketed without authorization. That authorization process requires toxicology data, behavioral evidence, youth‑use modeling, and proof of manufactured quality. WHO’s report mentions regulation mainly as something that is absent or lagging—yet fails to engage seriously with the one jurisdiction where regulation is neither hypothetical nor permissive, but actively science‑driven. 

Perhaps the most striking omission in WHO’s narrative is what the FDA actually considered when granting authorization.

The FDA explicitly reviewed national youth‑usage data and concluded that youth use of nicotine pouches remains low, even as adult uptake has grown and flavored products are available. According to the 2024 U.S. National Youth Tobacco Survey, only 1.8% of middle‑ and high‑school students reported current nicotine pouch use, a figure that did not increase significantly from the previous year. Cigarette smoking, meanwhile, fell to historic lows, and overall youth tobacco use declined.

The FDA did not ignore flavors; it assessed them directly. The agency authorized nicotine pouches in multiple flavors and strengths only after determining that the benefits for adult smokers who switch to pouches outweighed the risks (including the risk of youth initiation). This is not laissez‑faire policy—this is conditional approval backed by post‑market surveillance, marketing restrictions, and the threat of enforcement if youth uptake rises.

WHO’s report, by contrast, treats flavors as inherently incompatible with public health, despite empirical evidence from a heavily regulated market where flavors coexist with low youth use and declining smoking. 

WHO’s report focuses on packaging, digital marketing, influencer culture, and lifestyle imagery, drawing heavily on cross‑country advertising analyses and market trends. These concerns are not frivolous. Marketing matters, and history justifies skepticism toward the tobacco industry.

But a report that claims to guide global policy cannot afford to exclude comparative regulatory outcomes. The U.S. case demonstrates that nicotine pouches can be strictly regulated, scientifically reviewed, and conditionally authorized while maintaining low youth prevalence. Ignoring the U.S. example does not strengthen WHO’s case—it weakens it. 

Instead of asking “Does nicotine pouch adoption increase because of marketing?”, a more useful question would be: 
Under what regulatory conditions can lower‑risk nicotine products displace smoking without driving youth uptake? 

The FDA has attempted to answer that question empirically. WHO barely acknowledges it. 

WHO’s approach in this report reflects a familiar pattern: when evidence is incomplete or uncomfortable, precaution becomes prohibition by default. But precaution without proportionality risks brushing over important distinctions—between smoking and smoke‑free use, between youth initiation and adult cessation, and between unregulated markets and regulated ones. 

Ironically, WHO's stance may undermine public health goals. Smoking remains far deadlier than any non‑combustible nicotine product. In the U.S., the FDA’s review explicitly found that authorized nicotine pouches contain substantially lower levels of harmful constituents than cigarettes and smokeless tobacco, with corresponding reductions in cancer and disease risk.

A global health authority should not shy away from acknowledging when a regulator applies rigorous science and reaches nuanced conclusions. 

Is it fair to criticize WHO for publishing this report? Yes—not because WHO is wrong to scrutinize marketing, but because it is incomplete to do so without engaging with real‑world regulatory evidence that challenges its conclusions. 

The FDA’s decisions do not prove nicotine pouches are harmless. But they do prove something else: it’s possible to regulate, evaluate, and control these products based on data. 

If WHO wants to lead global tobacco control in an era of rapidly evolving products, it cannot afford to make assumptions or treat regulatory science as an inconvenience. Evidence‑based public health policy demands comparison, not omission—and debate, not dogma. 

Until then, WHO’s latest report only tells half the story.